Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel for Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Clinicaltrials.gov identifier:
NCT03981796
Metastatic endometrial cancer
Study Contact Information:
For additional information, please contact: US GSK Clinical Trials Call Center by phone: 877-379-3718 or by email: [email protected]
Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel for Recurrent or Primary Advanced Endometrial Cancer (RUBY)
About the Study
This study for people with III or IV endometrial cancer will look at how well the combination of the dostarlimab (Jemperli), the niraparib () and chemotherapy works compared with chemotherapy alone. NOTE: This study is no longer enrolling people.
NOTE: This study is no longer enrolling people.
NOTE: This study is no longer enrolling people.